Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ChemoCentryx: An Intriguing Rare Disease Player In 2020

Positive trial results are always a good thing, but is this newly hyped stock worth it?

ChemoCentryx Jumped by 348%. Is It a Buy?

ChemoCentryx Brings Hope To Vasculitis Patients, Steroid Therapy Can Play A Smaller Role

ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.

ChemoCentryx Up on Encouraging Rare Disease Candidate Data

The company unveiled positive data for the most advanced drug in its pipeline.

Here's Why ChemoCentryx Skyrocketed 278% Today

Dick's Sporting Goods

Nutanix

Find out how three stocks in very different sectors all posted solid gains.

Why Nutanix, Dick's Sporting Goods, and ChemoCentryx Jumped Today

-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --      -- Significantly reduced glucocorticoid toxicity --

ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis

-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G

Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2019 Results - Earnings Call Transcript

Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.

Is This Small-Cap Biotech a Buy Before 2020?

MOUNTAIN VIEW, Calif., Sept.  24, 2019  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET in New York City.

ChemoCentryx to Host R&D Day on October 1, 2019

ChemoCentryx: Fighting Steroids On Steroids

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results - Earnings Call Transcript

InflaRx

InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for skin disorder Hidradentis Suppurativa.

InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx

Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.

Why ChemoCentryx Shares Crashed 19.1% Today

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ChemoCentryx (CCXI) Moves to Buy: Rationale Behind the Upgrade

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q1 2019 Results - Earnings Call Transcript

ChemoCentryx saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

News for Chemocentryx Stock (CCXI)